Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to post its quarterly earnings results after the market closes on Tuesday, December 12th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.10) per share for the quarter.
Shares of Arrowhead Pharmaceuticals (ARWR) opened at $3.33 on Tuesday. Arrowhead Pharmaceuticals has a fifty-two week low of $1.20 and a fifty-two week high of $4.54. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03.
A number of analysts recently commented on the company. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. BidaskClub lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target on the stock in a report on Monday, November 27th. Chardan Capital reiterated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $3.17.
TRADEMARK VIOLATION WARNING: “Arrowhead Pharmaceuticals (ARWR) to Release Earnings on Tuesday” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/12/05/arrowhead-pharmaceuticals-arwr-to-release-earnings-on-tuesday.html.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.